Mariner
TGTX icon

Mariner’s TG Therapeutics TGTX Stock Holding History

Mariner’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.8M Sell
32,836
-266
-0.8% -$10.9K ﹤0.01% 1554
2026
Q1 		$1.1M Buy
33,102
+7,633
+30% +$227K ﹤0.01% 1901
2025
Q4 		$759K Sell
25,469
-23
-0.1% -$751 ﹤0.01% 2143
2025
Q3 		$921K Buy
25,492
+219
+0.9% +$7.21K ﹤0.01% 1972
2025
Q2 		$910K Sell
25,273
-9,945
-28% -$370K ﹤0.01% 1867
2025
Q1 		$1.39M Buy
35,218
+547
+2% +$18.4K ﹤0.01% 1457
2024
Q4 		$1.04M Sell
34,671
-12
-0% -$344 ﹤0.01% 1611
2024
Q3 		$811K Buy
34,683
+9,533
+38% +$208K ﹤0.01% 1766
2024
Q2 		$447K Buy
25,150
+300
+1% +$4.79K ﹤0.01% 2125
2024
Q1 		$378K Hold
24,850
– – ﹤0.01% 2243
2023
Q4 		$424K Buy
+24,850
New +$289K ﹤0.01% 2057
2023
Q3 		– Sell
-21,100
Closed -$524K – 3018
2023
Q2 		$524K Hold
21,100
– – ﹤0.01% 1705
2023
Q1 		$317K Buy
21,100
+1,500
+8% +$22.8K ﹤0.01% 2024
2022
Q4 		$232K Buy
+19,600
New +$142K ﹤0.01% 2240
2017
Q1 		– Sell
-24,116
Closed -$112K – 610
2016
Q4 		$112K Sell
24,116
-1,870
-7% -$11K 0.01% 542
2016
Q3 		$201K Buy
25,986
+6,900
+36% +$44.4K 0.01% 554
2016
Q2 		$116K Buy
19,086
+800
+4% +$6.5K 0.01% 517
2016
Q1 		$156K Buy
18,286
+255
+1% +$2.23K 0.01% 488
2015
Q4 		$215K Buy
18,031
+3,600
+25% +$45.5K 0.01% 404
2015
Q3 		$145K Hold
14,431
– – 0.01% 499
2015
Q2 		$239K Sell
14,431
-600
-4% -$9.5K 0.01% 455
2015
Q1 		$233K Buy
15,031
+874
+6% +$13.2K 0.02% 350
2014
Q4 		$224K Buy
+14,157
New +$184K 0.02% 342

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Mariner's TGTX Position: Q2 2026 in Review

Mariner reduced its TG Therapeutics (TGTX) stake by 0.8% in Q2 2026, selling an estimated $10.9K and leaving 32,836 shares worth $1.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1554.

Mariner first reported a position in TGTX in Q4 2014 and has held it in 23 quarters since. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Mariner held 32,836 shares of TG Therapeutics worth $1.8M as of Q2 2026.
  • Mariner sold 266 TG Therapeutics shares in Q2 2026, an estimated $10.9K.
  • TG Therapeutics made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #1554 holding.
  • Mariner first reported a position in TG Therapeutics in Q4 2014 and has held it in 23 quarters since.
  • 429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.